Sven Francque

Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital
When
26th-27th May 2022
Where
London, UK
London Heathrow Marriott Hotel
Global Engage is pleased to announce the 5th Global NASH Congress, which will be taking place on the 26th and 27th of May 2022 in London.
Endorsed by the:
An increasing number of people are being diagnosed with nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) each year, and the primary method of treatment is weight loss. With no approved medicines on the market, the drug development race is intensifying. The pathogenesis of NASH is still not fully understood, and definitive diagnostic methods are invasive, so development has been slow.
However, promising developments in research will hopefully bolster drug development and other methods
of treatment. Examples of such developments include improved in vivo liver models, non-invasive diagnostic biomarkers and a better understanding of the disease’s mechanisms. This year’s congress will focus on these exciting advancements, as well as on the challenges of preclinical and clinical research in NASH. There will also be sessions covering regulation and business development, as well as a showcase of the most promising therapeutics in development.
Attracting experts working in all areas of nonalcoholic steatohepatitis, the conference will examine the latest research and development in pathogenesis, diagnosis and treatment of the disease. Featuring small group roundtable discussions and ample networking time, the event provides an excellent opportunity to meet and collaborate with senior representatives from industry, hospitals and universities. During the two-day conference, there will be more than 30 expert-led presentations, interactive roundtable discussions exploring key issues, and a dynamic exhibition room filled with technology providers showcasing their technologies.
“I really enjoyed the scientific content of the conference with news from providers and Pharma organisations.” Delegate Pharma Company
“There was a good variety of speakers & content with ample networking opportunities” NHS Delegate
“A very good spread of content with topics that were applicable to a wide audience.”Academic delegate
“Well organised, varied content covering the main aspects of NASH and drug development.” Speaker
“I appreciated the broad spectrum of areas within NASH from clinical trials and biomarker to scientific new projects. The conference provided a nice overview of the field as of today.” Sponsor
This programme creates a collaborative environment in which you can create enduring relationships across the full range of disciplines engaged in NASH research & drug discovery and development.
• Advancing biomarkers for improved diagnosis, staging, monitoring and prognosis
• Review of current and potential biomarkers for each stage
• Evaluation of diagnostic tools
• Improving diagnostic accuracy for identification and clinical outcome
• Patient identification
• Selection of treatment
• Where are new biomarkers coming from?
• Liver biopsies
• Technology Focus – Imaging and other non-invasive technologies – overview, developments, and methods
• Quantitative analysis of samples
• Improved disease measurement, tracking and monitoring
• Pre-clinical development of NASH targets
• Target discovery and validation – New targets for treatment of NASH/ Fibrosis
• Optimising preclinical & translational models
• Model consistency
• Marrying model identification with disease stage
• Integration of clinical data to validate existing and identify novel mechanisms and targets
• Successful compounds in the clinic – How did they perform in preclinical models
Current NASH Drug Development case studies
• Improving patient recruitment and retention for clinical trials
• Novel clinical trial design – Uniformity and harmonization of trials
• Determining clinical endpoints
• Population screening
• Identifying correct treatment for stage
• What we learned from Phase 2/3 clinical trials in 2021/22
Exploring factors for advances in treatment – such as:
• Genetic susceptibility
• Metabolic syndrome
• Mitochondrial dysfunction and apoptosis
• Insulin resistance
• Gut microbiome
• Combination therapies
• Gut immune system
• Prevention and treatment – Tackling the root cause by improving awareness
• Utilizing nutrition and lifestyle factors
• Current regulatory guidance, interaction, and expectations for the future
• Regulatory pathways for approval of products
• Harmonizing clinical development and the regulatory landscape
Senior Vice President, Global Drug Discovery, Novo Nordisk, Denmark
The Slesinger Professor of Molecular Neuroscience, The Hebrew University of Jerusalem, Israel
Product Manager, E-Scopics, France
Chief Scientific Researcher, Resonance Health, Australia
NASH Program Director, Global Liver Institute, USA
Director of Clinical Research and Development, SomaLogic, Inc.
Senior Scientist, Gilead Sciences, USA
Chief Scientific Officer, Julius Clinical and Professor of Clinical Epidemiology, University Medical Center (UMC) Utrecht, The Netherlands
Consultant Histopathologist
Royal Free London NHS Foundation Trust, UK
Chief Scientific Officer – Imaging & AI, Resonance Health
Product Application Specialist, Keen Eye, France
Product Lead Immune and Inflammatory and Diseases, European Medicines Agency
ELPA President, European Liver Patients’ Association
Chief Medical Officer, Hepion Pharmaceuticals Inc
Professor of Metabolic Biology, Nutritional Sciences and Toxicology, University of California
Merinoff Endowed Chair and Co-Director for The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research
Senior Director, Regulatory Affairs, AstraZeneca
Associate Professor, Department of Translational and Precision Medicine, Sapienza University of Rome
Senior Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford
Professor, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island
Senior Clinical Research Fellow in Pathology and Consultant Histopathologist, University of Edinburgh
Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital
Professor in Pathology, Chair, Pathology Department, Beaujon Hospital, Clichy, Inserm
Chief Medical Officer, Galectin Therapeutics
Pinto Full Professor of Medicine, Faculty of Medicine, University of Lisbon
Chief Medical Officer, Altimmune
Executive Vice President of Non Clinical Development, Manufacturing Operations and Project Management, Poxel SA
Professor, Department of Gastroenterology and Hepatology, University of Ghent
Assistant Professor, Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon
Professor of Hepatology, Director of Research, Blizard Institute, Queen Mary University of London
Chief Medical Officer and President, Research & Development, Madrigal Pharmaceuticals
VP Liver Discovery, InSphero, Switzerland
Senior Vice President, Global Drug Discovery, Novo Nordisk, Denmark
The Slesinger Professor of Molecular Neuroscience, The Hebrew University of Jerusalem, Israel
Product Manager, E-Scopics, France
Chief Scientific Researcher, Resonance Health, Australia
NASH Program Director, Global Liver Institute, USA
Director of Clinical Research and Development, SomaLogic, Inc.
Senior Scientist, Gilead Sciences, USA
Chief Scientific Officer, Julius Clinical and Professor of Clinical Epidemiology, University Medical Center (UMC) Utrecht, The Netherlands
Consultant Histopathologist
Royal Free London NHS Foundation Trust, UK
Chief Scientific Officer – Imaging & AI, Resonance Health
Product Application Specialist, Keen Eye, France
Product Lead Immune and Inflammatory and Diseases, European Medicines Agency
ELPA President, European Liver Patients’ Association
Chief Medical Officer, Hepion Pharmaceuticals Inc
Professor of Metabolic Biology, Nutritional Sciences and Toxicology, University of California
Merinoff Endowed Chair and Co-Director for The Institute for Bioelectronic Medicine, Feinstein Institutes for Medical Research
Senior Director, Regulatory Affairs, AstraZeneca
Associate Professor, Department of Translational and Precision Medicine, Sapienza University of Rome
Senior Research Fellow, Nuffield Department of Primary Care Health Sciences, University of Oxford
Professor, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island
Senior Clinical Research Fellow in Pathology and Consultant Histopathologist, University of Edinburgh
Chairman, Division of Gastroenterology and Hepatology, Antwerp University Hospital
Professor in Pathology, Chair, Pathology Department, Beaujon Hospital, Clichy, Inserm
Chief Medical Officer, Galectin Therapeutics
Pinto Full Professor of Medicine, Faculty of Medicine, University of Lisbon
Chief Medical Officer, Altimmune
Executive Vice President of Non Clinical Development, Manufacturing Operations and Project Management, Poxel SA
Professor, Department of Gastroenterology and Hepatology, University of Ghent
Assistant Professor, Department of Biochemistry and Human Biology, Faculty of Pharmacy, University of Lisbon
Professor of Hepatology, Director of Research, Blizard Institute, Queen Mary University of London
Chief Medical Officer and President, Research & Development, Madrigal Pharmaceuticals
VP Liver Discovery, InSphero, Switzerland
Please contact [email protected] for more information about speaking opportunities.
Download the agendaUpdated 1 May 2022
Masks & hand sanitiser will be available at the registration desk.
The meeting is at the end of May. It will be conducted in accordance with the guidance issued at that time from the Department of Health.
At a minimum, it is a condition of entry to the meeting that you have had at least two vaccinations against Covid-19 or that you have had a negative antigen test result taken on 24th or 25th May 2022.
We will require you to complete a declaration confirming your vaccination or test status.
All conference sessions
Lunches and refreshments
Access to exhibition room
All networking forums
e-documentation pack
3 for the price of 2 offer
5 pass discounted price £360/£700 per person Academic/Industry
Discount applied automatically when registering places at once. If you do not know all the attendees complete this form
Not applicable for solution provider companies or compatible with any other offers or discount codes
Option 1 – Please phone +44 (0) 1865 671957 ext. 207 and we will take your details over the phone
Option 2 – Please complete the form below to pay online
Don’t forget our 3 for 2 and 5 pass discount offer! Details above
To help us comply with GDPR regulations, please register using your official institution email address and not a personal email.
*Discount is not available to representatives of organisations offering services and / or business & technology solutions or business consultants. Please contact [email protected].
£1,099.00
Standard registration for those not in the categories below
£599.00
£1,299.00
Fee for representatives of organisations offering services and/or business & technology solutions and also to business consultants.
Poster presentation sessions will take place in breaks and alongside the other breakout sessions of the conference. Your presentation will be displayed in a dedicated area, with the other accepted posters from industry and academic presenters.
We also issue a poster eBook to all attendees containing your full abstract, and you can share your poster as a PDF after the meeting if you desire (optional).
Whether looking for funding, employment opportunities or simply wanting to share your work with a like-minded and focused group, these are an excellent way to join the heart of this congress.
In order to present a poster at the congress, you must be registered as a delegate. Please note that there is limited space available and poster space is assigned on a first come first served basis (subject to checks and successful registration).
SUBMISSION INSTRUCTIONS
We will require the form (downloadable below) to be submitted by 6th May 2022. This is the formal deadline however space is another limiting factor so early application is recommended. Therefore please contact us with any questions you have as soon as possible.
POSTER COMPETITION – CLOSING DATE 6th May 2022
1. Submit your entry prior to the closing deadline (1 entry per person)
2. Two entries for the 5th Global NASH Congress will be selected by the judges
3. The winner of the poster presentation will be given a 15-minute speaking position on the conference agenda and will be notified in advance of the meeting
4. The judge(s) will make the decision based on the abstract(s) submitted
5. The winner will also receive a certificate from the organisers
6. Representatives from solution provider organisations or experts already speaking on the program are not eligible to enter the competition but are welcome to present posters at the meeting as normal
SomaLogic’s industry-leading proteomics platform enables simultaneous assessment of 7,000 proteins and 18 clinical metrics from a single blood draw. Detect steatosis, ballooning, inflammation, and fibrosis without a liver biopsy using our SomaSignal™ NASH Tests, the only validated blood test for measuring all four NASH components. Discover non-invasive biomarkers for NASH and comorbidities with our pioneering 7,000-protein SomaScan® Assay. We are your partner in biomarker discovery and clinical monitoring for NASH, diabetes, heart disease, and more.
https://somalogic.com/life-sciences/
Keen Eye is an AI platform company aiming at bringing decision-support and GxP compliant image analysis services for accelerating drug development, from preclinical to clinical phases, and improving therapies in inflammatory diseases and oncology. Keen Eye brings accurate, standardized and undiscovered tissue insights through its cloud-based computational pathology platform which optimizes user processes and scales up their capacity.
×Resonance Health is a medtech company headquartered in Australia that specializes in the development and commercialization of innovative MRI related technologies. Our flagship product, FerriScan®, provides a highly precise measurement of Liver Iron Concentration, essential for the care of Thalassaemia patients and other iron overload related conditions. Our portfolio includes Core Lab and AI Powered products to partner with radiologists and clinicians for screening, diagnosis, and management of patients in a variety of clinical settings.
http://www.resonancehealth.com/
Julius Clinical is a global Academic CRO with a distinct focus on unmet medical needs. Our scientific expertise combined with creative operational solutions uniquely equips us to assist in providing answers for today’s clinical drug development challenges. As a response to the NASH conundrum, we initiated: GRIP ON NASH, a multinational research initiative in which 10,000 patients at risk will be screened for the presence of NAFLD and NASH.
https://www.juliusclinical.com/areas-of-expertise/nonalcoholic-steatohepatitis/
Metabolon, Inc., reveals biological insights otherwise unseen. Over nearly two decades, Metabolon has built the best metabolomic competency in the world. Today, Metabolon enables, accelerates and supports drug development through biomarker discovery, understanding mechanism of action, patient stratification, and more, as evidenced by >2,000 publications, numerous high-impact case studies and customer testimonials.
Metabolon’s scalable, customizable metabolomics solutions support discovery through clinical trials and product life-cycle management. Metabolon’s diverse patient data set is equipped to deliver biologically relevant insights to address some of the most challenging and pressing questions in the life sciences. Metabolon is ISO 9001:2015 certified for analytical and diagnostic testing of biological specimens, certified by CLIA and accredited by the College of American Pathologists for diagnostic testing on human specimens. The company, founded in 2000, is based in Research Triangle Park, North Carolina. For more information, please visit www.metabolon.com/ or follow on LinkedIn or Twitter.
×LifeNet Health LifeSciences leads the way in human in vitro biology for both non-diseased and diseased research needs. LifeNet Health LifeSciences combines innovative, technology-driven research and development programs to create human tissue and cell-based research products and services.
https://lnhlifesciences.org/
Accelerated Enrollment Solutions (AES) helps biopharmaceutical companies overcome patient enrollment and research site challenges by combining a powerful patient recruiting solution with more than 160 clinical research sites located throughout the world. As a business of PPD, part of Thermo Fisher Scientific, we are committed to optimizing each step in the patient journey and delivering best-in-class site performance to bring our customers greater certainty to clinical trial delivery.
×E-Scopics dematerializes Ultrasound to democratize its use by all healthcare professionals. Products are downloadable App services that connect to, and control smart digital probes. E-Scopics further differentiates clinically with unique “imaging biomarkers”. The company’s first App, the Hepatoscope, is dedicated to the non-invasive assessment of liver diseases, of which NASH. The Hepatoscope offers an assessment of liver stiffness, attenuation and sound speed, which may be used as an aid to manage chronic liver disease patients.
×InSphero is a Swiss-based phenomics biotech that has been perfecting 3D-cell-based drug discovery platforms and scaffold-free 3D organ-on-a-chip technologies for more than 10 years. InSphero deploys its patent-pending technologies for highly scalable drug discovery programs against liver diseases, e.g. NASH and NAFLD. InSphero’s strategic partnering model is based on multi-tiered, custom programs with pharma, biotech and academic organizations and led to collaborations with 17 of the world’s top 20 pharmaceutical companies.
×Ambition: Develop a specific and lasting demand for your brand, by acting on its environment and implementing a bold health communication strategy.
A specialist of high value-added scientific content, TERRA FIRMA optimizes the source effect by relying on KOLs. To bring out THE specific unmet health need to which your brand provides THE solution and therefore amplify its demand, TERRA FIRMA disseminates messages to your targets through all existing vectors.
×Select which delegates you would like to meet in a series of prearranged twenty-minute one-to-one meetings, held during breakout sessions from the main conference agenda. Our conference team will be available at the sessions to ensure all your meetings take place on time.
Host your own half or full day pre or post event workshop to a dedicated audience around a subject of your choice. Global Engage will assist with the marketing of your workshop to provide a guaranteed audience.
Market to our event database and/or increase brand awareness by taking a poster position or sponsoring the poster sessions. This can be supplemented by branding options such as placing your logo on the meeting background screen.
Showcase your technologies and products throughout the conference in the dedicated exhibition areas where all refreshment breaks and lunches take place, as well as the networking drinks reception.
Options include:
For further details please contact
Nick Best or Gavin Hambrook
Telephone +44 (0) 1865 849841
HEP Dynamics LLC is a consortium of senior consultants with extensive backgrounds in healthcare strategy, marketing, communications and marketing research. We shape strategies and drive thoughtful exchanges that create more dynamic discussions of liver diseases and select ultra-orphan conditions. Our clients manufacture and market biopharmaceuticals, diagnostics and non-invasive devices. In addition to our client-centered activities, HEP Dynamics is widely known as Executive Producer of Surfing the NASH Tsunami, the world’s leading podcast on commercial and medical issues in Fatty Liver diseases. SurfingNASH posts weekly episodes, excerpts these into shorter conversations and provides same-day coverage of major Fatty Liver meetings.
×To improve the lives of individuals and families impacted by liver disease through promoting innovation, encouraging collaboration, and scaling optimal approaches to help eradicate liver diseases.
×ELPA is an umbrella association based in Brussels, representing 32 members from 25 countries. It is also the biggest European association representing advocating for liver patients’ voices and unmet needs for more than 15 years.
Our aim is to promote the interests of people with liver disease and in particular: to highlight the size of the problem; to promote awareness and prevention; to address the low profile of liver disease as compared to other areas of medicine such as heart disease; to share the experience of successful initiatives; to work with professional bodies such as EASL and with the EU to ensure that treatment and care are harmonized across Europe to the highest standards. ELPA is also involved in 10 European projects playing a crucial role in the field of dissemination and communication.
We raise awareness and educate Canadians about the risks, causes and complications of fatty liver disease and help those already diagnosed with nonalcoholic fatty liver disease (NAFLD), metabolic associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis (NASH) by advocating for access to approved treatments and care.
https://www.fattyliver.ca/
Hep magazine and HepMag.com are the go-to sources for educational and social support for people living with liver diseases like hepatitis C, hepatitis B, hepatitis A and NASH. Launched in 2010, the website is devoted to combating the stigma and isolation surrounding liver diseases and offers news, in-depth reporting, educational tools, care resources, and peer-to-peer networking.
×Pharma Journalist is a paramount B2b online magazine platform exhibiting targeted and succinct information concerning the world of Pharmaceutical Industry, keeping a tab on the updated and latest updates and trends concerning the field.
×Clocate.com is a leading international directory for worldwide conferences and exhibitions. Clocate.com is equipped with a unique and comprehensive search that helps you find easily any event in any category or location. Each event includes detailed information, like, description, dates, location, map, prices, link to the event’s website and more…
If you search for a conference or exhibition in areas such as Industry and manufacturing, Health and medicine, Technology and IT, Business and finance, sciences, education, services (banking, insurance, tourism, Hospitality and more), government, environment, life style and arts, you’ll find it in Clocate.com.
Global Information, Inc. is an information service company holding offices in 6 countries and have sales agency contracts with over 300 research companies around the world. We sell 30,000 market research reports published by these publishers and accept custom-made researches.
×Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.